Late-breaking clinical trials presented at the 2005 and 2006 annual scientific meetings of
the ACC, AHA, and European Society of Cardiology, as well as selected other data, were …

Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and …

Myocardial infarction is a major cause of death and disability worldwide. Coronary atherosclerosis
is a chronic disease with stable and unstable periods. During unstable periods with …

Background—Angiotensin-converting enzyme (ACE) inhibitors are generally prescribed by
physicians in doses lower than the large doses that have been shown to reduce morbidity …

Background The prognosis of patients hospitalized with acute myocardial ischemia is quite
variable. We examined the value of serum levels of cardiac troponin T, serum creatine kinase …

Background Nesiritide is approved in the United States for early relief of dyspnea in patients
with acute heart failure. Previous meta-analyses have raised questions regarding renal …

Background—Appropriate treatment policies should include an accurate estimate of a
patient’s baseline risk. Risk modeling to date has been underutilized in patients with acute …

Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac
complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of …

Background— Although previous work has suggested that anemia is associated with an
increased mortality in selected patients with congestive heart failure (CHF), little is known about …

Background The effect of intensified platelet inhibition for patients with unstable angina or
myocardial infarction without ST-segment elevation who do not undergo revascularization has …